What we cover

We track every meaningful development in the GLP-1 space — Wegovy, Ozempic, Mounjaro, Zepbound, Foundayo, retatrutide, and the wave of compounded operators that came in during the shortage. Our editorial mix is roughly 30% FDA & regulation, 30% clinical science, 20% market & pricing, 15% patient safety, and 5% opinion.

Editorial independence

We are funded primarily through a sponsorship arrangement with Teleios Health, a physician-led GLP-1 program. Sponsored content is clearly labelled as such on every page where it appears. The Teleios team has no editorial control over our reporting.

Medical review board

Every clinical claim we publish is reviewed by:

  • Dr. Ana Lisa Carr, MD — Internal medicine. NPI: 1689841744.
  • Dr. Kelly Tenbrink, MD — Family medicine, weight management. NPI: 1346482684.

Corrections policy

If you spot a factual error, email corrections@theglpthruth.com. We document corrections inline at the bottom of the affected article within 48 hours.

How we use images

Every article published on The GLP Truth uses a unique editorial image, never reused across pieces. We track image assignments in a versioned manifest so the cron-driven content engine never recycles imagery — even as we publish multiple times per week.